VRise is a precision oncology company pursuing ground-breaking discovery and development of novel small molecules. We target pathways that determine cancer growth and proliferation using a proprietary discovery engine.

VRise has identified 2 promising candidates, VRTX126-KRASG12 inhibitor and VRTX531-USP1 inhibitor, which have demonstrated exceptional in-vivo antitumor activity and each of these compounds are ready to enter IND-enabling studies